Retatrutide
Also known as: LY3437943, Triple G
A triple agonist targeting GLP-1, GIP, and glucagon receptors. Represents the next evolution beyond dual agonists like tirzepatide, showing unprecedented weight loss in trials.
Mechanism of Action
Retatrutide activates three receptors: GLP-1 for appetite suppression and glucose control, GIP for enhanced insulin response and metabolic effects, and glucagon for increased energy expenditure and fat oxidation. The triple mechanism provides synergistic effects.
Research Summary
Phase 2 trials showed up to 24% weight loss at 48 weeks, the highest seen in any obesity drug trial. Studies demonstrate significant improvements in metabolic markers, liver fat reduction, and glycemic control. Phase 3 trials underway.
Research Protocols
Note: Doses from clinical trials
Common Doses
- •Starting: 0.5mg weekly
- •Titrating up to 12mg weekly (highest studied)
Duration
Long-term use expected
Administration
Subcutaneous injection weekly
Side Effects & Considerations
- •Nausea
- •Diarrhea
- •Vomiting
- •Constipation
- •Similar GI profile to other incretins
- •Phase 3 will provide more safety data
References
Want updates on Retatrutide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.